Natus Medical Incorporated (NTUS): Price and Financial Metrics
NTUS Price/Volume Stats
|Current price||$32.96||52-week high||$33.93|
|Prev. close||$32.93||52-week low||$20.90|
|Day high||$33.07||Avg. volume||325,002|
|50-day MA||$32.59||Dividend yield||N/A|
|200-day MA||$27.26||Market Cap||1.14B|
NTUS Stock Price Chart Interactive Chart >
Natus Medical Incorporated (NTUS) Company Bio
Natus Medical is a provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. The company was founded in 1987 and is based in Pleasanton, California.
NTUS Latest News Stream
|Loading, please wait...|
NTUS Latest Social Stream
View Full NTUS Social Stream
Latest NTUS News From Around the Web
Below are the latest news stories about NATUS MEDICAL INC that investors may wish to consider to help them evaluate NTUS as an investment opportunity.
DUBLIN , June 22, 2022 /PRNewswire/ -- The "Global Neurology Devices Market Report 2022" report has been added to ResearchAndMarkets.com''s offering. The global neurology devices market is expected to grow from $13.94 billion in 2021 to $15.91 billion in 2022 at a compound annual growth rate (CAGR) of 14.2%. The market is expected to grow to $25.75 billion in 2026 at a compound annual growth rate (CAGR) of 12.8%. Major companies in the neurology devices market include Medtronic Inc., Stryker Corporation, Terumo Corporation, Integra Lifesciences, Boston Scientific Corporation, Penumbra, Inc., B. Braun Group, Nevro, LivaNova, PLC, and Natus Medical. The neurology devices market consists of sales of neurology devices and related services by entities (organizations, sole traders, and partne...
Q1-2022 Key ResultsRevenue (millions)$119.8 • Total revenue increased 4.2% compared to Q1 2021• Generated $8.9 million in operating cash flowGAAP EPS$0.06 Non-GAAP EPS$0.22 MIDDLETON, Wis., May 05, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, today announced financial results for the three
Shares of Natus Medical were soaring Monday after the company announced it would be acquired by investment firm ArchiMed for approximately $1.2 billion. Natus (ticker: NTUS ) is a maker of medical devices for diagnosing and treating disorders affecting the brain and nervous systems. ArchiMed will pay Natus shareholders $33.50 in cash for each share of common stock they own, a 29% premium to the stock’s closing price on April 14.
By Sam Boughedda
Highlights: • Transaction values Natus Medical, Incorporated at approximately $1.2 billion total equity value• Pre-announces preliminary financial results for the first quarter ended March 31, 2022 MIDDLETON, Wis., April 18, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today th
NTUS Price Returns